John Houston, PhD
The FDA has granted a fast track designation to ARV-110, a PROTAC®
protein degrader, for use as a treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have disease progression following ≥2 systemic therapies.
Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer. Arvinas, Inc. Published May 29, 2019. https://bit.ly/2wrTs44. Accessed May 29, 2019.
... to read the full story